fenofibrate cipla fenofibrate 145 mg tablet blister pack
cipla australia pty ltd - fenofibrate, quantity: 145 mg - tablet, film coated - excipient ingredients: docusate sodium; hypromellose; sodium lauryl sulfate; sucrose; silicified microcrystalline cellulose; crospovidone; magnesium stearate; lactose monohydrate; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate cipla is indicated as an adjunct to diet in the treatment of:,- hypercholesterolaemia;,- types ii, iii, iv and v dyslipidaemia;,- dyslipidaemia assocated with type 2 diabetes.
cipla pain relief paracetamol and codeine phosphate hemihydrate 8 tablet blister pack
cipla australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 8 mg - tablet, uncoated - excipient ingredients: erythrosine aluminium lake; lactose monohydrate; magnesium stearate; potato starch; povidone; docusate sodium; colloidal anhydrous silica - for the temporary relief of acute moderate pain in patients over the age of 12 years
cipla hydrocortisone hydrocortisone (as sodium succinate) 100 mg powder for injection vial
cipla australia pty ltd - hydrocortisone sodium succinate, quantity: 133.7 mg (equivalent: hydrocortisone, qty 100 mg) - injection, powder for - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate - when oral therapy is not feasible, and the strength, form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, [invented name] powder for injection is indicated for intravenous or intramuscular use in the following conditions: 1. endocrine disorders ? primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplements may be necessary, particularly when synthetic analogues are used). ? preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful ? shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected ? congenital adrenal hyperplasia ? nonsuppurative thyroiditis ? hypercalcaemia associated with cancer. 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: ? post-traumatic osteoarthritis ? synovitis of osteoarthritis ? rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) ? acute and subacute bursitis ? epicondylitis ? acute nonspecific tenosynovitis ? acute gouty arthritis ? psoriatic arthritis ? ankylosing spondylitis. 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: ? systemic lupus erythematosus ? systemic dermatomyositis (polymyositis) ? acute rheumatic carditis. 4. dermatological diseases ? pemphigus ? severe erythema multiforme (stevens-johnson syndrome) ? exfoliative dermatitis ? bullous dermatitis herpetiformis ? severe seborrhoeic dermatitis ? severe psoriasis ? mycosis fungoides. 5. allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: ? bronchial asthma ? drug hypersensitivity reactions ? contact dermatitis ? urticarial transfusion reactions ? atopic dermatitis ? serum sickness ? acute noninfectious laryngeal oedema (adrenaline is the drug of first choice). 6. ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye, such as: ? herpes zoster ophthalmicus ? iritis, iridocyclitis ? chorioretinitis ? diffuse posterior uveitis and choroiditis ? optic neuritis ? sympathetic ophthalmia ? anterior segment inflammation ? allergic conjunctivitis ? allergic corneal marginal ulcers ? keratitis. 7. gastrointestinal diseases to tide the patient over a critical period of the disease in: ? ulcerative colitis (systemic therapy) ? regional enteritis (systemic therapy). 8. respiratory diseases ? symptomatic sarcoidosis ? loeffler?s syndrome not manageable by other means ? berylliosis ? fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy ? aspiration pneumonitis. 9. haematological disorders ? acquired (autoimmune) haemolytic anaemia ? erythroblastopenia (rbc anaemia) ? idiopathic thrombocytopenic purpura in adults (iv only; im administration is contraindicated) ? secondary thrombocytopenia in adults ? congenital (erythroid) hypoplastic anaemia. 10. neoplastic diseases for palliative management of: ? leukaemias and lymphomas in adults ? acute leukaemia in childhood. 11. oedematous states ? to induce diuresis or remission of proteinuria in the nephrotic syndrome, without uraemia, of the idiopathic type or that due to lupus erythematosus. 12. miscellaneous ? tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurological or myocardial involvement.
cipla-zidovudine capsules
cipla medpro (pty) ltd - capsules - see ingredients - each capsule contains zidovudine 100,0 mg
cipla-oseltamivir capsules
cipla medpro (pty) ltd - capsules - see ingredients - each capsule contains oseltamivir phosphate equivalent to oseltamivir 75,0 mg
cipla zoledronic acid injection
cipla medpro (pty) ltd - injection - see ingredients - each vial contains zoledronate trisodium equivalent to zoledronic acid 4,0 mg
imatinib 400 milligram capsules hard
cipla (eu) limited - imatinib mesilate - capsules hard - 400 milligram - other cytostatics - antineoplastic agents; protein kinase inhibitor - it is indicated for the treatment of: paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid; leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment; paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated; phase or blast crisis; adult patients with ph+ cml in blast crisis; adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy; adult patients with relapsed or refractory ph+ all as monotherapy; adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived; growth factor receptor (pdgfr) gene re-arrangements; adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement
cipla tadalafil 2.5 tadalafil 2.5 mg film-coated tablet blister pack
cipla australia pty ltd - tadalafil, quantity: 2.5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hyprolose; magnesium stearate; microcrystalline cellulose; lactose monohydrate; sodium lauryl sulfate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - cipla tadalafil is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males
cipla tadalafil 10 tadalafil 10 mg film-coated tablet blister pack
cipla australia pty ltd - tadalafil, quantity: 10 mg - tablet - excipient ingredients: magnesium stearate; croscarmellose sodium; sodium lauryl sulfate; lactose monohydrate; microcrystalline cellulose; hyprolose; titanium dioxide; hypromellose; triacetin; iron oxide yellow - cipla tadalafil is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males
cipla tadalafil 5 tadalafil 5 mg film-coated tablet blister pack
cipla australia pty ltd - tadalafil, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; hyprolose; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - cipla tadalafil is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males